Universidad Miguel Hernández de Elche-ko ikertzaileekin lankidetzan egindako argitalpenak (39)

2018

  1. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

    European Journal of Pharmaceutical Sciences, Vol. 117, pp. 193-203

  2. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation

    European Journal of Pharmaceutical Sciences, Vol. 119, pp. 200-207

  3. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits

    European Journal of Pharmaceutical Sciences, Vol. 120, pp. 123-132

2017

  1. Enhancing Oral Absorption of β-Lapachone: Progress Till Date

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 42, Núm. 1

  2. IVIVC approach based on carbamazepine bioequivalence studies combination

    Pharmazie, Vol. 72, Núm. 8, pp. 449-455

2016

  1. Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles

    AAPS Journal, Vol. 18, Núm. 6, pp. 1550-1561

  2. Importance and applications of cell-and tissue-based in vitro models for drug permeability screening in early stages of drug development

    Concepts and Models for Drug Permeability Studies: Cell and Tissue based In Vitro Culture Models (Elsevier Inc.), pp. 3-29

  3. Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 41, Núm. 6, pp. 795-806

  4. Population pharmacokinetic model of lithium and drug compliance assessment

    European Neuropsychopharmacology, Vol. 26, Núm. 12, pp. 1868-1876

  5. Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjects

    British Journal of Clinical Pharmacology, pp. 92-107

2015

  1. Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets

    Molecular Pharmaceutics, Vol. 12, Núm. 9, pp. 3194-3201

  2. Blood-brain barrier and drug delivery

    Advances in Non-Invasive Drug Delivery to the Brain (Future Medicine Ltd.), pp. 6-20

  3. Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties

    Journal of Medicinal Chemistry, Vol. 58, Núm. 15, pp. 5825-5841

  4. Drug gastrointestinal absorption in rat: Strain and gender differences

    European Journal of Pharmaceutical Sciences, Vol. 78, pp. 198-203

  5. Importance and applications of cell- and tissue-based in vitro models for drug permeability screening in early stages of drug development

    Concepts and Models for Drug Permeability Studies: Cell and Tissue based in Vitro Culture Models (Elsevier), pp. 3-29

  6. In vitro methods for assessing drug access to the brain

    Advances in Non-Invasive Drug Delivery to the Brain (Future Medicine Ltd.), pp. 44-61

  7. In vitro-in vivo correlations: General concepts, methodologies and regulatory applications

    Drug Development and Industrial Pharmacy, Vol. 41, Núm. 12, pp. 1935-1947

  8. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class i Drug

    Molecular Pharmaceutics, Vol. 12, Núm. 9, pp. 3167-3174

  9. Nueva estrategia computacional - experimental para la clasificación biofarmacéutica de fármacos y su implementación para la obtención de medicamentos genéricos y productos farmacéuticos de avanzada.

    Anales de la Academia de Ciencias de Cuba, Vol. 5, Núm. 3

  10. Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

    European Journal of Pharmaceutical Sciences, Vol. 74, pp. 86-94